Twenty-one percent CAGR. In life sciences, that's not a growth rate — it's a revolution.
The global DNA read, write and edit market was valued at $21.4 billion in 2024. By 2030, it's projected to hit $67.7 billion. That's more than tripling in six years.
What's behind these numbers? The convergence of three transformative technologies: next-generation DNA sequencing (read), gene synthesis (write) and CRISPR-based genome editing (edit). Together, they're reshaping medicine, agriculture and industrial biotechnology.
On the "read" side, genomic sequencing is moving from specialty applications into routine clinical care — enabling earlier detection of chronic diseases, pathogen surveillance and personalized treatment planning.
On the "write" side, declining synthesis costs are unlocking synthetic biology applications that seemed theoretical a decade ago.
And on the "edit" side, CRISPR has crossed from the lab into the clinic. Approved gene editing therapies are treating real patients. Next-generation CAR-T treatments built on CRISPR technology are in development. In vivo gene editing is progressing. CRISPR-based diagnostic platforms are emerging.
North America leads with 43.5% market share. The competitive landscape includes giants like Illumina, Thermo Fisher, Roche and Merck KGaA alongside genome editing pioneers like Beam Therapeutics and Vertex, and synthesis leaders like GenScript and IDT.
The challenges — complex regulations, high instrument costs, CRISPR off-target effects — are real. But the trajectory is clear.
**Want to understand where this market is headed?** Download the free overview of our report *Global DNA Read, Write, and Edit Market* for complete technology analysis, competitive landscape and market forecasting.
[Download the Free Report Overview →]